Study reveals cancer-killing benefits of popular obesity treatment

This article has been reviewed in accordance with Science X’s editorial processes and policies. The editors highlight the following attributes while ensuring content authenticity:


peer-reviewed publications


Credits: CC0 Public Domain

The Kathleen Lonsdale Institute for Human Health at Maynooth University has published a study on the benefits of GLP-1, a popular anti-obesity drug.

Previous studies have shown that obese people have a higher risk of developing cancer. This is partly because the cancer-fighting immune cells, known as “natural killer (NK)” cells, are rendered useless by the disease.

In a new study conducted by Dr. Andrew Hogan and his team at the University of Maynooth Lonsdale Health Institute, a common gold-standard pharmacological treatment for obesity, a glucagon-like peptide (GLP-1) analogue, actually reversed It turns out that you can. Her NK cell functions in the body, including the ability to kill cancer cells.

The World Health Organization estimates that 13% of the world’s adult population suffers from obesity. A disease that increases the risk of developing cancer. These cancers account for his 40% of all cancers diagnosed in the United States each year.

Research published in obesityand also show that the restored cancer-killing effect of NK cells is independent of GLP-1’s main weight loss function, so it appears that the treatment is directly igniting the NK cell engine.

Dr. Andrew E. Hogan, associate professor and principal investigator at the Lonsdale Institute for Human Health at Maynooth University, said of the findings: Obesity and it appears to have real, measurable benefits for those currently taking the drug.”

“These findings are understandably welcomed by those living with obesity and looking for safe and effective treatments, but the recent surge in popularity associated with the benefits of GLP-1 treatment is not the only option. Given that global and prominent celebrities have commented on its success, demand has increased, resulting in a global shortage of the drug.

“We hope to bring this under control so as many people living with obesity as possible can start their own treatment with this beneficial drug.”

Connor de Barra, Ph.D., a student of immunology at Maynooth College and an Irish Research Council scholar who led research in Dr. You may develop a variety of health problems, such as these, which can be very detrimental to your quality of life. These findings point to potential benefits in addition to weight loss.”

Professor Donal O’Shea, HSE National Lead for Obesity & Principal Investigator, said: Our findings suggest that benefits of this treatment family may extend to reduced cancer risk for obese patients receiving GLP-1 therapy. ”

Dr. Hogan will present these findings at the 30th European Obesity Congress in Dublin on May 20th.

For more information:
Glucagon-like peptide-1 therapy in obese patients restores natural killer cell metabolism and effector function. obesity (2023). DOI: 10.1002/oby.23772


Journal information:

Courtesy of Maynooth University

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *